CJC-1295 without DAC 5mg – Mod GRF 1-29 Research Peptide

CJC-1295 without DAC 5mg is a research-grade peptide supplied as a lyophilized powder in a sterile multidose vial with a stated purity of ≥99%. It is commonly associated in research-product literature with the designation Mod GRF 1-29 or Modified GRF(1-29) and is studied within the broader field of growth hormone-releasing hormone (GHRH), peptide-receptor, and endocrine signaling research.

The 5mg formulation provides researchers with a defined research material for laboratory and analytical investigations involving peptide biology and GHRH-related signaling pathways.

Published research on CJC-1295-related compounds provides scientific context for investigating modified GHRH analogues and their interactions with the growth hormone-releasing factor receptor. However, researchers should distinguish findings relating to specific CJC-1295 formulations rather than assuming that results from one formulation automatically apply to every CJC-1295-related material.

For Research Use Only. Not for human or veterinary use.

Product Specifications

What Is CJC-1295 without DAC?

CJC-1295 without DAC is commonly described as a modified GHRH-related research peptide and is frequently associated with the designation Mod GRF 1-29.

The “without DAC” terminology distinguishes this material from CJC-1295 formulations containing the Drug Affinity Complex (DAC). This distinction is relevant when reviewing scientific literature or comparing research materials because different CJC-1295 formulations can have different molecular characteristics.

Early research identified CJC-1295 as a modified human growth hormone-releasing factor-related compound and investigated its activity at the GRF receptor in experimental models. The published study characterized CJC-1295 as a modified hGRF(1-29)-related analogue and examined its stability and biological activity.

The broader literature on GHRH analogues also includes research into receptor binding, structure-activity relationships, and signaling.

For scientific reproducibility, researchers should rely on product identity information, analytical documentation, and available Certificate of Analysis data rather than product naming alone.

CJC-1295 without DAC 5mg Research Applications

CJC-1295 without DAC 5mg may be relevant to controlled laboratory research involving several areas of peptide and endocrine biology.

GHRH Signaling Research

Growth hormone-releasing hormone signaling is an established area of endocrine research. Experimental models can investigate interactions between GHRH-related peptides and their receptors, downstream signaling, and molecular mechanisms associated with endocrine regulation.

CJC-1295-related compounds have been investigated within this broader research field, providing a basis for continued laboratory study of GHRH receptor biology.

Endocrine Pathway Research

The GHRH pathway forms part of the broader endocrine signaling network associated with the somatotropic axis.

Laboratory research may examine peptide-receptor interactions, intracellular signaling, molecular responses, and relationships between GHRH-related signaling and other endocrine pathways.

Growth Hormone Biology

CJC-1295-related peptides are studied in connection with GHRH and growth hormone biology. Research may investigate receptor activity, signaling mechanisms, peptide structure, and endocrine responses in controlled experimental models.

Results from studies of CJC-1295 with DAC, CJC-1295 without DAC, or other GHRH analogues should be interpreted according to the exact compound investigated.

Peptide-Receptor Research

CJC-1295 without DAC can be relevant to laboratory investigations involving peptide-receptor interactions.

Research may examine ligand-receptor binding, receptor-mediated signaling, cellular responses, and downstream molecular pathways associated with GHRH-related peptides.

Muscle Physiology Research

The GHRH and growth hormone signaling systems are also relevant to experimental studies of muscle physiology and cellular function.

Research in this area can investigate endocrine signaling mechanisms and cellular responses without implying a particular performance or body-composition outcome in humans.

Metabolic Research

Growth hormone and endocrine signaling intersect with multiple metabolic pathways. CJC-1295-related research may therefore be incorporated into laboratory studies examining relationships between peptide signaling, endocrine regulation, and cellular metabolism.

Cellular and Molecular Research

The compound may also be relevant to molecular investigations involving peptide structure, receptor signaling, cellular physiology, and biochemical pathways.

CJC-1295 without DAC and Mod GRF 1-29

The terms CJC-1295 without DAC and Mod GRF 1-29 are frequently used together in commercial research-product literature.

However, terminology can vary between suppliers. Researchers should therefore avoid relying solely on a commercial product name when precise molecular identity is important.

For reproducible research, laboratories should evaluate the available analytical documentation, identity information, purity specification, and batch-specific Certificate of Analysis where available.

This is particularly important when comparing CJC-1295 without DAC with products identified as CJC-1295 containing DAC.

CJC-1295 without DAC 5mg Research-Grade Quality

This CJC-1295 without DAC 5mg research compound is supplied with a stated purity of ≥99%.

The material is provided as a lyophilized powder in a sterile multidose vial. Defined specifications can assist laboratories in maintaining consistent records and material identification throughout research workflows.

Product Features

• 5mg research-grade formulation
• ≥99% stated purity
• Lyophilized powder
• Sterile multidose vial
• Refrigerated storage at 2°C–8°C
• Protection from heat, moisture, and direct sunlight
• Suitable for laboratory and analytical research
• Suitable for molecular and biochemical investigations
• Defined product specifications for research documentation

Researchers should review available batch documentation and Certificate of Analysis information where applicable before incorporating research materials into experimental workflows.

Storage

Store CJC-1295 without DAC 5mg refrigerated at 2°C–8°C.

Protect the sealed product from:

• Heat
• Moisture
• Direct sunlight
• Excessive environmental exposure

Laboratories should follow their established procedures for research-material storage, documentation, environmental control, and quality management.

Scientific Research Context

The scientific literature surrounding CJC-1295 and GHRH analogues provides a broader framework for understanding the research area.

An early PubMed-indexed study investigated CJC-1295 as a modified hGRF(1-29)-related analogue and examined its interaction with the growth hormone-releasing factor receptor in experimental models.

More recent literature has discussed CJC-1295 without DAC alongside other peptides affecting the GH–IGF-1 axis, while also highlighting the distinction between research evidence and the use of unregulated peptide products.

Researchers can consult peer-reviewed CJC-1295 research literature when evaluating evidence concerning GHRH signaling, receptor biology, and related peptide pathways.

Canadian Research and Regulatory Context

BioMatrix Compounds supplies this product strictly as a research-use compound.

Health Canada currently identifies CJC-1295 among examples of unauthorized injectable peptide drugs in Canada. Its April 2026 advisory states that unauthorized injectable peptide products have not been assessed by Health Canada for safety, effectiveness, or quality.

Health Canada subsequently announced in July 2026 that a permanent injunction had been obtained against Canlab Research concerning the sale of unauthorized injectable peptides in Canada. The agency states that selling unauthorized prescription drugs in Canada is illegal.

The designation “Research Use Only” should therefore not be interpreted as an exemption from applicable Canadian regulatory requirements.

Researchers and purchasers are responsible for determining the requirements applicable to their intended laboratory activities and for complying with applicable federal, provincial, institutional, and laboratory rules.

Related Research Peptides

Researchers investigating GHRH-related signaling may also explore the CJC-1295 without DAC + Ipamorelin research formulation available from BioMatrix Compounds.

This provides a separate research formulation containing CJC-1295 without DAC and Ipamorelin, allowing researchers to distinguish a standalone CJC-1295-related material from a defined peptide combination.

Researchers investigating other peptide signaling pathways may also explore KPV 10mg, representing a separate research context involving peptide biology and cellular signaling.

Research Use Only

For Research Use Only.

CJC-1295 without DAC 5mg is intended exclusively for laboratory research and analytical purposes. It is not intended for human or veterinary use.

This product is not intended for consumption, diagnosis, treatment, cure, or prevention of any disease or medical condition. Information provided on this page is for research and educational context only and should not be interpreted as medical advice, therapeutic guidance, dosage guidance, administration instructions, or a recommendation for personal use.

Researchers and purchasers are responsible for determining whether this research material is appropriate for their intended laboratory application and for complying with all applicable federal, provincial, institutional, and laboratory requirements.